CA2751364C - Methods for the detection of jc polyoma virus - Google Patents

Methods for the detection of jc polyoma virus Download PDF

Info

Publication number
CA2751364C
CA2751364C CA2751364A CA2751364A CA2751364C CA 2751364 C CA2751364 C CA 2751364C CA 2751364 A CA2751364 A CA 2751364A CA 2751364 A CA2751364 A CA 2751364A CA 2751364 C CA2751364 C CA 2751364C
Authority
CA
Canada
Prior art keywords
jcv
pml
subject
variant
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2751364A
Other languages
English (en)
French (fr)
Other versions
CA2751364A1 (en
Inventor
Leonid Gorelik
Alexey Lugovskoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42542341&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2751364(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of CA2751364A1 publication Critical patent/CA2751364A1/en
Application granted granted Critical
Publication of CA2751364C publication Critical patent/CA2751364C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CA2751364A 2009-02-05 2010-02-05 Methods for the detection of jc polyoma virus Active CA2751364C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15031009P 2009-02-05 2009-02-05
US61/150,310 2009-02-05
PCT/US2010/000342 WO2010090757A1 (en) 2009-02-05 2010-02-05 Methods for the detection of jc polyoma virus

Publications (2)

Publication Number Publication Date
CA2751364A1 CA2751364A1 (en) 2010-08-12
CA2751364C true CA2751364C (en) 2017-06-20

Family

ID=42542341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2751364A Active CA2751364C (en) 2009-02-05 2010-02-05 Methods for the detection of jc polyoma virus

Country Status (11)

Country Link
US (2) US20130101985A9 (enExample)
EP (1) EP2394163B1 (enExample)
JP (1) JP2012517017A (enExample)
CN (2) CN104316696A (enExample)
AU (1) AU2010210979B2 (enExample)
BR (1) BRPI1016273A2 (enExample)
CA (1) CA2751364C (enExample)
ES (1) ES2842425T3 (enExample)
NZ (1) NZ594973A (enExample)
SG (2) SG173201A1 (enExample)
WO (1) WO2010090757A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
AU2007224228B2 (en) 2006-03-03 2013-09-19 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2010090757A1 (en) 2009-02-05 2010-08-12 Biogen Idec Ma Inc. Methods for the detection of jc polyoma virus
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PT2524060T (pt) 2010-01-11 2018-03-28 Biogen Ma Inc Ensaio para a deteção de anticorpos contra o vírus jc
PT3575792T (pt) 2011-05-31 2023-02-28 Biogen Ma Inc Método de avaliação do risco de lmp
PT2734544T (pt) 2011-07-18 2021-03-16 Us Health Métodos e composições para inibir a patologia associada a poliomavírus
EP2548567A1 (en) 2011-07-22 2013-01-23 Universitätsklinikum Hamburg-Eppendorf Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
EP2636746A1 (en) * 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
DK2828292T3 (da) 2012-03-20 2019-01-02 Biogen Ma Inc Jcv-neutraliserende antistoffer
DK2828284T3 (da) 2012-03-20 2019-06-11 Biogen Ma Inc Jcv-neutraliserende antistoffer
US9631243B2 (en) 2012-06-18 2017-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for identifying JC virus
CN104936980B (zh) 2012-12-31 2019-06-07 生物控股有限公司 用于治疗和预防多瘤病毒相关的疾病的重组人抗体
NO2774991T3 (enExample) * 2013-03-06 2018-05-05
US20160002743A1 (en) * 2013-03-15 2016-01-07 Biogen Ma Inc. High resolution melting analysis assay for the detection of viral dna
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHOD FOR ASSESSING A PML RISK
WO2015095770A1 (en) 2013-12-20 2015-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic jc polyomavirus compositions and methods of use
US20200197544A1 (en) * 2017-04-26 2020-06-25 Biogen Ma Inc. Jcv imaging methods and compositions
CN112442553A (zh) * 2020-10-27 2021-03-05 深圳市罗湖区人民医院 一种用于JCPyV检测与分型的试剂盒及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3767755B2 (ja) * 1995-06-23 2006-04-19 エーザイ株式会社 抗ｊｃウイルス抗体
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
AU715973B2 (en) 1996-01-26 2000-02-10 Regents Of The University Of California, The Polymeric film, assay and method for direct colorimetric detection of analytes
DE10131145B4 (de) * 2001-06-28 2005-07-14 Innovent E.V. Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
JP4840792B2 (ja) 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 ＪＣウイルスａｇｎｏを対象としたＰＭＬの治療
EP1785433A4 (en) 2004-07-01 2008-10-01 Tokyo Inst Tech VIRAL PARTICLE-LIKE CONSTRUCTION AND PROCESS FOR FORMING THE SAME IN PHYSIOLOGICAL CONDITIONS
JP4757103B2 (ja) 2005-06-13 2011-08-24 学校法人関西文理総合学園 試料中のウイルスを検出する方法およびシステム
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
EP1951888B1 (en) 2005-11-09 2012-09-05 PrimeraDx, Inc. Multiplexed quantitative detection of pathogens
US7769230B2 (en) * 2006-11-30 2010-08-03 Eastman Kodak Company Producing low resolution images
WO2008077511A1 (en) 2006-12-22 2008-07-03 Karolinska Institutet Innovations Ab Human polyomavirus and methods of diagnosis and treatment
JP2008249433A (ja) 2007-03-29 2008-10-16 Kansai Bunri Sogo Gakuen 被験物質に対するプローブの結合親和性を測定する方法及びその利用
US20110118340A1 (en) 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
WO2010090757A1 (en) 2009-02-05 2010-08-12 Biogen Idec Ma Inc. Methods for the detection of jc polyoma virus
EA201490368A1 (ru) 2011-07-29 2014-07-30 Байоджен Айдек Ма Инк. Анализ для определения днк вируса jc
AR095089A1 (es) 2013-01-30 2015-09-30 Biogen Idec Inc Ensayo de detección de adn de virus jc

Also Published As

Publication number Publication date
US9696307B2 (en) 2017-07-04
EP2394163B1 (en) 2020-08-19
US20120258443A1 (en) 2012-10-11
US20150219651A1 (en) 2015-08-06
US20130101985A9 (en) 2013-04-25
SG2014009120A (en) 2014-03-28
CN102369436B (zh) 2014-10-22
SG173201A1 (en) 2011-08-29
AU2010210979A1 (en) 2011-09-22
AU2010210979B2 (en) 2015-12-10
BRPI1016273A2 (pt) 2020-12-01
EP2394163A1 (en) 2011-12-14
EP2394163A4 (en) 2012-08-01
WO2010090757A1 (en) 2010-08-12
CN102369436A (zh) 2012-03-07
ES2842425T3 (es) 2021-07-14
NZ594973A (en) 2012-05-25
CN104316696A (zh) 2015-01-28
JP2012517017A (ja) 2012-07-26
CA2751364A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
US9696307B2 (en) Methods for the detection of JC polyoma virus
Zhang et al. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
Song et al. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms
Wang et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
Dang et al. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins
Pötzsch et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies
CN111995676A (zh) 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用
JP6735005B2 (ja) グリピカンエピトープおよびその使用
KR102671155B1 (ko) Ns1 단백질의 결합 단백질
Shang et al. NRP1 is a receptor for mammalian orthoreovirus engaged by distinct capsid subunits
Li et al. Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
Chang et al. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern
EA029346B1 (ru) Моноклональное антитело человека против белка vp1 вируса jc
JP5755239B2 (ja) Ｈ−１パルボウイルスに結合する抗体
Su et al. A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif
CN114573691A (zh) 一株人源中和抗体或其抗原结合片段及其应用
Ssebyatika et al. Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice
Diotti et al. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy
CN114249819A (zh) 猫泛白细胞减少症病毒抗体、含有猫泛白细胞减少症病毒抗体的试剂盒及应用
Zhao et al. Cross-species recognition of bat coronavirus RsYN04 and cross-reaction of SARS-CoV-2 antibodies against the virus
Wang et al. A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron
Lanning et al. Discovery of three novel neutralizing antibody epitopes on the human astrovirus capsid spike and mechanistic insights into virus neutralization
Wang et al. Molecular blueprints of the Langya virus attachment and fusion glycoproteins
WO2023174976A1 (en) Broadly neutralizing antibodies against hepatitis e virus
Guo et al. Construction of immune human library and screening of neutralizing antibodies specific to glycoprotein of severe fever with thrombocytopenia syndrome virus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150115

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250124

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250124

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260122